{"nctId":"NCT01553318","briefTitle":"Novel Use of (Oral) Ketotifen for the Treatment of Fibromyalgia: A Pilot Study","startDateStruct":{"date":"2012-03"},"conditions":["Fibromyalgia"],"count":51,"armGroups":[{"label":"Active Ketotifen","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ketotifen"]},{"label":"Placebo for Ketotifen","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (Sugar Pill)"]}],"interventions":[{"name":"Ketotifen","otherNames":["Zaditor"]},{"name":"Placebo (Sugar Pill)","otherNames":["Placebo","Sugar Pill"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nIn order to qualify the subject:\n\n1. must have been diagnosed with fibromyalgia by a medical doctor\n2. must be between the ages of 18 to 65 years of age\n3. must have a weekly overall body pain average score ≥ 4\n4. must pass a screening questionnaire that calculates a physical impairment of ≥ 10\n5. must be on stable doses of his/her current medication for at least past four weeks\n6. must limit any changes in his/her medication(s) (e.g., dose change, addition or discontinuation of any medication that effects the central nervous system, e.g., benzodiazepines, sedative/hypnotic, etc. ) during the 10-week study period unless medically necessary\n7. must report all medication including herbal supplements and over-the-counter medications, e.g. cold medication, eye drops, etc. that he/she is currently taking to a member of the research team\n8. must be willing to maintain a medication diary provided to him/her during the 10-week study period\n9. must be willing to abstain (not take) any fibromyalgia related medication including over-the-counter for at least 8-hours prior to each of the two testing visits (Otherwise, he/she may take these medication(s) immediately after pain sensitivity testing has been completed and as prescribed in-between visits)\n10. must agree to use a proven method of contraception to prevent pregnancy throughout this study\n\nExclusion Criteria:\n\nThe subject will not be allowed to participate if:\n\n1. he/she has a history of seizures\n2. he/she has atopic dermatitis (also called eczema) or chronic urticaria (hives)\n3. he/she has chronic thrombocytopenia (a low blood platelet count)\n4. she is currently pregnant, are planning to become pregnant, or is breastfeeding\n5. he/she has been diagnosed by a psychiatrist with Schizophrenia or bipolar disorder\n6. he/she has been diagnosed with another major rheumatic conditions (i.e. rheumatoid arthritis, systemic lupus erythematosus, scleroderma and/or other connective tissue diseases)\n7. he/she plans to undergo an elective surgery within the study timeline\n8. he/she is in the process of filing, or plan to file for disability benefits within the study timeline\n9. his/her screening labs results are abnormal (i.e., elevated SGPT and low platelet count)\n10. he/she is currently using any anti-allergy drugs (ophthalmic or oral histamine antagonist), leukotriene inhibitors (e.g., montelukast) or prednisone","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Weekly Average Pain Score on the Visual Analog Scale at Week 10","description":"Change in weekly average pain score from baseline to week 10 (range from -10 to +10): interpretation= the more negative the value is, the larger reduction in pain severity at week 10 is","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.33","spread":"1.92"},{"groupId":"OG001","value":"-1.54","spread":"1.93"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Evoked Pain Score at Week 10","description":"Change in evoked pain score from baseline to week 10 (scale range -20 to +20): interpretation= the more negative the value is, the larger the reduction in sensitivity to pressure pain stimuli","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"0.36"},{"groupId":"OG001","value":"-0.27","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Fibromyalgia Impact Questionnaire","description":"Change in global symptom severity \\[scale range from -100 to +100\\] = the more negative the value is, the greater the improvement in overall symptom severity","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.13","spread":"19.54"},{"groupId":"OG001","value":"-12.27","spread":"18.12"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Blood Levels of IL-8, MCP-1 and Eotaxin at Week 10","description":"Change in peripheral blood levels of IL-8, MCP-1 and Eotaxin from baseline to week 10","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":24},"commonTop":["Fatigue"]}}}